A Phase 1b Study Evaluating the Safety, Tolerability and Preliminary Anti-tumor Activity of NT-I7 (efineptakin alfa) a Long-acting Human IL-7, post-Tisagenlecleucel (Kymriah®) in Subjects with Relapsed/Refractory Large B-cell Lymphoma

Administered By

Awarded By

Contributors

Start/End

  • September 28, 2021 - October 31, 2026